REPLIMUNE GROUP, INC. Peo Total Comp Amt
REPLIMUNE GROUP, INC. (REPL) reported Peo Total Comp Amt of $5.85 million for the 12-month period ending 2026-03-31, per its DEF 14A filed 2026-07-29.
Financial Statements › Notes
ecd:PeoTotalCompAmt · last filed 2026-07-29
| Period end | Peo Total Comp Amt 12 month |
|---|---|
| 2026-03-31 | $5.85M DEF 14A · filed 2026-07-29 |
| 2025-03-31 | $3.70M DEF 14A · filed 2026-07-29 |
| 2024-03-31 | $6.02M DEF 14A · filed 2026-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |